Literature DB >> 9699127

Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma.

E Chiefari1, D Russo, D Giuffrida, G A Zampa, D Meringolo, F Arturi, I Chiodini, D Bianchi, M Attard, V Trischitta, R Bruno, P Giannasio, A Pontecorvi, S Filetti.   

Abstract

Medullary thyroid carcinoma (MTC) may occur either as a sporadic or familial (FMTC) disease. Multiple endocrine neoplasia (MEN) type 2, inherited as an autosomal dominant disease, is characterized by coexistence of MTC with other endocrine neoplasia. Activating mutations of the RET proto-oncogene, involving the somatic or the germinal cell lineage, are found in both inherited and acquired forms. In this study, RET mutations were screened in 47 individuals either affected by MTC or belonging to families with hereditary MTC. Exons 10, 11, 13, 14, 15 and 16 of the RET gene were amplified by polymerase chain reaction and examined by DNA sequence and/or restriction enzyme analysis to detect mutations in purified amplicons. Six MEN 2A families with a germline mutation at codon 634, one FMTC family carrying a mutation at codon 618 and two MEN 2B families with a mutation at codon 918 were identified. In affected members of a MEN 2A family no known RET mutations were observed. Besides, we identified a germline mutation in a patient with apparently sporadic MTC and in two out of three sons, indicating the presence of a sporadic misclassified familial disease. In all of the families examined we were able to distinguish the affected vs unaffected (not at risk) members. A somatic mutation of codon 918 was detected in three out of ten patients with apparently sporadic MTC.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9699127     DOI: 10.1007/BF03350771

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  19 in total

1.  Family screening in medullary thyroid carcinoma presenting without a family history.

Authors:  B A Ponder; N Finer; R Coffey; C L Harmer; M Maisey; M G Ormerod; M E Pembrey; M A Ponder; P Rosswick; S Shalet
Journal:  Q J Med       Date:  1988-04

2.  Presence of mutations in all three ras genes in human thyroid tumors.

Authors:  H G Suarez; J A du Villard; M Severino; B Caillou; M Schlumberger; M Tubiana; C Parmentier; R Monier
Journal:  Oncogene       Date:  1990-04       Impact factor: 9.867

3.  A case of metastatic medullary thyroid carcinoma: early identification before surgery of an RET proto-oncogene somatic mutation in fine-needle aspirate specimens.

Authors:  D Russo; F Arturi; E Chiefari; D Meringolo; D Bianchi; B Bellanova; S Filetti
Journal:  J Clin Endocrinol Metab       Date:  1997-10       Impact factor: 5.958

Review 4.  Application of genetic screening information to the management of medullary thyroid carcinoma and multiple endocrine neoplasia type 2.

Authors:  N Wohllk; G J Cote; D B Evans; H Goepfert; N G Ordonez; R F Gagel
Journal:  Endocrinol Metab Clin North Am       Date:  1996-03       Impact factor: 4.741

Review 5.  Seminars in medicine of the Beth Israel Hospital, Boston. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease.

Authors:  C Eng
Journal:  N Engl J Med       Date:  1996-09-26       Impact factor: 91.245

6.  Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains.

Authors:  M Takahashi; Y Buma; T Iwamoto; Y Inaguma; H Ikeda; H Hiai
Journal:  Oncogene       Date:  1988-11       Impact factor: 9.867

7.  The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis.

Authors:  C Eng; D Clayton; I Schuffenecker; G Lenoir; G Cote; R F Gagel; H K van Amstel; C J Lips; I Nishisho; S I Takai; D J Marsh; B G Robinson; K Frank-Raue; F Raue; F Xue; W W Noll; C Romei; F Pacini; M Fink; B Niederle; J Zedenius; M Nordenskjöld; P Komminoth; G N Hendy; L M Mulligan
Journal:  JAMA       Date:  1996-11-20       Impact factor: 56.272

8.  Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A.

Authors:  S A Wells; D D Chi; K Toshima; L P Dehner; C M Coffin; S B Dowton; J L Ivanovich; M K DeBenedetti; W G Dilley; J F Moley
Journal:  Ann Surg       Date:  1994-09       Impact factor: 12.969

9.  Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence.

Authors:  C Romei; R Elisei; A Pinchera; I Ceccherini; E Molinaro; F Mancusi; E Martino; G Romeo; F Pacini
Journal:  J Clin Endocrinol Metab       Date:  1996-04       Impact factor: 5.958

10.  Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity.

Authors:  J R Farndon; G S Leight; W G Dilley; S B Baylin; R C Smallridge; T S Harrison; S A Wells
Journal:  Br J Surg       Date:  1986-04       Impact factor: 6.939

View more
  13 in total

1.  RET proto-oncogene mutation in a mixed medullary-follicular thyroid carcinoma.

Authors:  F Orlandi; E Chiefari; P Caraci; A Mussa; I Gonzatto; P De Giuli; D Giuffrida; A Angeli; S Filetti
Journal:  J Endocrinol Invest       Date:  2001-01       Impact factor: 4.256

2.  Evaluation of a DHPLC-based assay for rapid detection of RET germline mutations in Italian patients with medullary thyroid carcinoma.

Authors:  I Torrente; F Arturi; L D'Aloiso; A Colosimo; A De Luca; E Ferretti; D Russo; E Chiefari; D Scarpelli; M Bisceglia; B Dallapiccola; S Filetti
Journal:  J Endocrinol Invest       Date:  2004-02       Impact factor: 4.256

3.  Early diagnosis of medullary thyroid carcinoma: is systematic calcitonin screening appropriate in patients with nodular thyroid disease?

Authors:  Giuseppe Costante; Sebastiano Filetti
Journal:  Oncologist       Date:  2011-01-06

4.  Nine novel germline gene variants in the RET proto-oncogene identified in twelve unrelated cases.

Authors:  Syed A Ahmed; Karen Snow-Bailey; W Edward Highsmith; Weimin Sun; Raymond G Fenwick; Rong Mao
Journal:  J Mol Diagn       Date:  2005-05       Impact factor: 5.568

5.  A Drosophila model of multiple endocrine neoplasia type 2.

Authors:  Renee D Read; Paul J Goodfellow; Elaine R Mardis; Nancy Novak; Jon R Armstrong; Ross L Cagan
Journal:  Genetics       Date:  2005-06-18       Impact factor: 4.562

6.  Overexpression of genes involved in miRNA biogenesis in medullary thyroid carcinomas with RET mutation.

Authors:  Cinzia Puppin; Cosimo Durante; Marialuisa Sponziello; Antonella Verrienti; Valeria Pecce; Elisa Lavarone; Federica Baldan; Antonio Francesco Campese; Amelie Boichard; Ludovic Lacroix; Diego Russo; Sebastiano Filetti; Giuseppe Damante
Journal:  Endocrine       Date:  2014-02-26       Impact factor: 3.633

7.  Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutations.

Authors:  Thereasa A Rich; Lei Feng; Naifa Busaidy; Gilbert J Cote; Robert F Gagel; Mimi Hu; Camilo Jimenez; Jeffrey E Lee; Nancy Perrier; Steven I Sherman; Steven G Waguespack; Anita Ying; Elizabeth Grubbs
Journal:  Thyroid       Date:  2014-06-06       Impact factor: 6.568

Review 8.  RET proto-oncogene mutations in thyroid carcinomas: clinical relevance.

Authors:  F Pacini; R Elisei; C Romei; A Pinchera
Journal:  J Endocrinol Invest       Date:  2000-05       Impact factor: 4.256

Review 9.  Familial non-medullary thyroid carcinoma: an update.

Authors:  Vânia Nosé
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

10.  Clinical characteristics and genetic screening of an extended family with MEN2A.

Authors:  E Algün; N Abaci; M Kösem; C Kotan; B Köseoğlu; H Boztepe; R Sekeroğlu; H Aslan; C Topal; H Ayakta; I Uygan; F Alagöl; N Erginel-Unaltuna; H Aksoy
Journal:  J Endocrinol Invest       Date:  2002 Jul-Aug       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.